China (Mainland)
lower price Parecoxib Sodium（198470-85-8） supply CAS NO.198470-85-8
- Min.Order: 1 Gram
- Payment Terms: L/C,D/A,D/P,T/T,Other
- Product Details
Keywords
- 198470-85-8
- Parecoxib Sodium
- Parecoxib
Quick Details
- ProName: lower price Parecoxib Sodium（198470-8...
- CasNo: 198470-85-8
- Molecular Formula: C19H17N2NaO4S
- Appearance: white powder
- Application: used for research
- DeliveryTime: 3 days
- PackAge: aluminum foil bag
- Port: shenzhen
- ProductionCapacity: 1 Metric Ton/Day
- Purity: 99%min
- Storage: Store in cool, dry, ventilated place
- Transportation: by sea or by air
- LimitNum: 1 Gram
- Related Substances: N/A
- Residue on Ignition: N/A
- Heavy Metal: N/A
- Valid Period: one year
- N/A: N/A
Superiority
www.wolcase.com
Details
-
Product Name Parecoxib sodium Synonyms N-[4-(5-Methyl-3-phenylisoxazol-4-yl)phenylsulfonyl]propionamide sodium salt CAS No. 198470-85-8 Molecular Formula C19H17N2O4S.Na Molecular Weight 392.4 Appearance White solid Melting point 273-275°C Assay 99% Introduction
Parecoxib is a water soluble and injectable prodrug of valdecoxib. It is marketed as Dynastat in the European Union. Parecoxib is a COX2 selective inhibitor in the same category as celecoxib (Celebrex) and rofecoxib (Vioxx). As it is injectable, it can be used perioperatively when patients are unable to take oral medications. It is approved through much of Europe for short term perioperative pain control much in the same way ketorolac(Toradol) is used in the United States. However, unlike ketorolac, parecoxib has no effect on platelet function and therefore does not promote bleeding during or after surgery. In addition, ketorolac has a much higher gastrointestinal toxicity profile compared to most other nonsteroidal antiinflammatory drugs (NSAIDs) including ibuprofen and naprosyn. However, in the United States ketorolac is the only injectable NSAID, although it is banned in many European countries due to concerns about surgical bleeding and stomach ulcers after surgery.
All antiiflammatory medications in the U.S. carry the same warning regarding skin reactions, and none are approved for use during CABG surgery, so the reason for the FDA denying the approval of parecoxib remains unknown, but was likely related to political pressure from the US Congress to not approve another COX-2 selective inhibitor in the wake of the Vioxx affair. No COX-2 selective inhibitor has been approved in the US since that time, regardless of the safety profile of parecoxib in Europe. Efforts to try and find out the scientific rationale, or more likely the lack thereof, that the FDA used to justify the non-approval of parecoxib in the USA have proven futile due to secrecy issues.